Best Practices: Managing and Diagnosing Hypophosphatemia

This program is a series of five 60-minute monthly live, virtual webinars held monthly including live Q&A and available on-demand on Endocrine Society’s Center for learning platform. 

This program was funded through educational grants from Ultragenyx.

Each webinar will include 3-5 pre- and post-test questions, and will be certified for up to 1 AMA PRA Category 1 Credits and 1 ABIM MOC Points.

Registrants of this series will automatically be registered for each live webinar and will be sent login information 24-48 hours before the event. If you are unable to attend the live webinar, the recording will be available within 5-10 business days.

A Patient's Story

Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Identify optimal approaches to effectively evaluate pediatric and adult patients with hypophosphatemia.
  • Discuss treatment strategies for hypophosphatemic disorders in adult and pediatric patients

 

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Course opens: 
08/17/2020
Course expires: 
12/31/2021
Rating: 
5

Program

This program is a series of five 60-minute monthly live, virtual webinars held monthly including live Q&A and available on-demand on Endocrine Society’s Center for learning platform.  This program was funded through educational grants from Ultragenyx. Each webinar will include 3-5 pre- and post-test questions will be certified for up to 1 AMA PRA Category 1 Credits and 1 ABIM MOC Points.

Webinar 1 - Differential Diagnosis of Hypophosphatemic Disorders
August 27, 2020 @ 2:00pm-3:00pm ET
Pablo Florenzano, MD

Webinar 2 - Mechanism of FGF-23 Mediated Related Diseases
September 24, 2020 @ 2:00pm-3:00pm ET
Michael T. Collins, MD

Webinar 3 - Clinical Evaluation and Management of Pediatric Patients with Hypophosphatemic Disorders
October 29, 2020 @ 2:00pm-3:00pm ET
Rachel I. Gafni, MD

Webinar 4 - Clinical Evaluation and Management of Adult Patients with Hypophosphatemic Disorders
November 12, 2020 @ 2:00pm-3:00pm ET
Erik A. Imel, MD

Webinar 5 - New Approaches to Tumor Induced Osteomalacia
December 10, 2020 @ 2:00pm-3:00pm ET
Suzanne Jan De Beur, MD

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Laila S. Tabatabai, MD: Speaker: Radius, Amgen; Research Investigator: Ultragenyx Pharmaceuticals
Michael T. Collins, MD: Research Grant Support: NPS/Shire/Takeda, QED Therapeutics
Pablo Florenzano, MD:  Speaker, Ultragenyx Pharmaceuticals; Research, Ultragenyx Pharmaceuticals; Advisory Board Member, Kyowa Kirin 
Rachel I. Gafni, MD:  Research Investigator: Ultragenyx Pharmaceuticals, QED Therapeutics, Inozyme
Erik A. Imel, MD: Research Funding, Ultragenyx Pharmaceuticals, Pharmacosmos.  Advisory Board, Ultragenyx Pharmaceuticals, Pharmacosmos
Suzanne Jan De Beur, MD: Research Support, Ultragenyx Pharmaceutical, Mereo Biopharma; Advisory Board,  Ultragenyx Pharmaceutical, Kyowa Kirin; Consultant, Ultragenyx Pharmaceutical

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Deborah Sellmeyer, MD

The following SPC Committee members reported relevant financial relationships:
Andjela T. Drincic, MD: Advisory Board Member, Corcept
Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences
Amy Rothberg, MD: Spouse, consultant of Merck

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Katherine Araque, MD; Beret Ann Casey, MD; Jenny Blau, MD; Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

 

DISCLAIMERS USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT This educational activity is supported by educational grants from Ultragenyx.

Click "Start" to complete the meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.  

The Endocrine Society designates each webinar will to be certified for up to 1 AMA PRA Category 1 Credits and 1 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact. 

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


ABIM MAINTENANCE OF CERTIFICATION 

Successful completion of this CME activity series, which includes participation in the evaluation components, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program, for each webinar. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

REVIEW YOUR DIPLOMATE ABIM ID NUMBER(S)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):
    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update button below to add or correct your profile.
  2. Update 

ABP MAINTENANCE OF CERTIFICATION 

Successful completion of components two and three of this five-part CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program, for each of the two eligible webinars. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit. 

REVIEW YOUR DIPLOMATE ABP ID NUMBER(S)

In order to earn and report MOC points to the American Board of Pediatrics (ABP), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):
    Your ABP Number: [current-user:profile-profile:field-number-abp]*

    *If your ABP number is blank or incorrect as shown above, please click the Update button below to add or correct your profile.
  2. Update 

Registrants of this series will automatically be registered for each live webinar and will be sent login information 24-48 hours before the event. Following the event, you will have 10 days to complete the evaluation and receive credit.

If you are unable to attend the live webinar, the recording will be available within 5-10 business days.